Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
暂无分享,去创建一个
K. Facey | E. Nicod | J. Espín | A. O'Leary | A. Zaremba | S. Upadhyaya | E. Xoxi | E. Kent | Angèl Link | Inneke van de Vijver | Tatyana Benisheva | A. Vagoras